Metro International Biotech has dosed the first four patients in a Phase 1a clinical trial of MIB-725, a proprietary NAD booster targeting age-related diseases with initial focus on chronic kidney disease.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.